NORAD and breast cancer: Silencing H19 expression has been shown to sensitize doxorubicin-resistant MCF-7 cells to chemotherapy, indicating a potential similar function of NORAD and highlighting lncRNA targeting in sensitizing BC therapy-resistant cells [107].